Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MTCR: Liquidation/Final Distribution (no distribution notes by FINRA)
FINRA deleted symbol:
https://otce.finra.org/otce/dailyList?viewType=Deletions
MTCR delisted from the Nasdaq to the OTC:
https://otce.finra.org/otce/dailyList?viewType=Additions
Insider buying and a buyout… may be already baked in but probably not.
you sure hit the nail on the head with that brilliant conclusion... 4 month old news is going to make this dive now???
Yes lost big unfortunately hopefully a bounce PM the love/hate of biotech plays
MTCR -50%/AH on discontinuation of FXR/NASH program:
https://www.globenewswire.com/news-release/2021/10/21/2318743/0/en/Metacrine-Reports-Interim-Results-for-MET642-Phase-2a-Trial-in-Patients-with-NASH-and-Announces-a-Strategic-Re-Prioritization-of-Its-Clinical-Development-Programs.html
MTCR 1Q21 results—3/31/21_cash=$84.5M:
https://finance.yahoo.com/news/metacrine-accelerates-met409-clinical-development-200500397.html
MTCR starts phase-2a for MET642—the follow-on FXR agonist to MET409:
https://finance.yahoo.com/news/metacrine-initiates-phase-2a-trial-113000073.html
MET-409 phase-1b data in NASH don’t look so good:
#msg-162210410
Awesome sauce crude buddy, catchin' up on the DD with ya ty
Perfect! I'm playing way more big board this month than pennies! The money flow on big board runners has been utter insanity so far this month!
Metacrine shares are trading higher after the company announced it is presenting new data from its MET409 program in NASH at AASLD's The Liver Meeting Digital Experience.
Metacrine, Inc. is a United States-based biotechnology company. The Company is engaged in developing therapeutics for metabolic diseases. The Company leverages approximately two mechanistically distinct programs to target type 2 diabetes, NASH and other metabolic diseases and liver disorders. The Company focuses on advancing research in nuclear hormone receptors for treatment of metabolic diseases.
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
24
|
Created
|
10/12/20
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |